US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SpyGlass Pharma, Inc.

29.07

+0.47001.64%

Volume:41.55K

Turnover:1.21M

Market Cap:968.54M

PE:-17.34

High:29.56

Open:29.12

Low:28.75

Close:28.60

52wk High:32.44

52wk Low:17.06

Shares:33.32M

Float Shares:10.78M

Volume Ratio:1.05

T/O Rate:0.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6760

EPS(LYR):-17.9825

ROE:-67.71%

ROA:-37.23%

PB:4.17

PE(LYR):-1.62

Loading ...

Overview Company News Filings

SpyGlass Pharma Q2 FY26 Net Loss Widens to $19.9 Million; R&D Expenses Rise to $10.9 Million

Spyglass Pharma Q2 EPS USD -0.59

THOMSON REUTERS

Spyglass Pharma Q2 Pretax Profit USD -19.864 Million

THOMSON REUTERS

Stockland Reports Lapse of 42,313 Performance Rights

Solana price clears $80 resistance as technicals point to $90 next

Should Stockland’s A$250m Town Centre JV Shape the Income Story for ASX:SGP Investors?

Simply Wall St.

SpyGlass Pharma appoints Shannon Treviño as general counsel

Spyglass Pharma Appoints Shannon TreviÑO as General Counsel

THOMSON REUTERS

Is Stockland (ASX:SGP) Quietly Recasting Its Risk Profile With Morgan Stanley’s Capital-Light Partnership?

Simply Wall St.

Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing

THOMSON REUTERS

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)

SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat

SpyGlass Pharma to Participate in Upcoming Investor Conferences

Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)

Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027

THOMSON REUTERS

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

Spyglass Pharma publishes deck on long-acting intraocular drug delivery for glaucoma patients

SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate

Benzinga Earnings

Spyglass Pharma Q1 FY26 net loss widens 57% to $13.82 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/SGP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SGP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":29.07,"timestamp":1789658363881,"preClose":28.6,"halted":0,"volume":41553,"delay":0,"changeRate":0.01643356643356639,"floatShares":10781300,"shares":33317414,"eps":-1.676,"marketStatus":"Trading","change":0.47,"latestTime":"09-17 11:19:34 EDT","open":29.12,"high":29.555,"low":28.75,"amount":1211589.243252,"amplitude":0.028147,"askPrice":29.58,"askSize":200,"bidPrice":29.13,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":28.6,"postHourTrading":{"tag":"盘后","latestPrice":28.6,"preClose":28.6,"latestTime":"19:30 EDT","volume":13510,"amount":386386,"timestamp":1789601405100,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.050607},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGP\",,,,,undefined,":{"symbol":"SGP","floatShares":10781300,"roa":"-37.23%","roe":"-67.71%","lyrEps":-17.982467,"volumeRatio":1.050607,"shares":33317414,"dividePrice":0,"high":29.555,"amplitude":0.028147,"preClose":28.6,"low":28.75,"week52Low":17.06,"pbRate":"4.17","week52High":32.44,"institutionHeld":0,"latestPrice":29.07,"committee":0.428571,"eps":-1.676,"divideRate":0,"volume":41553,"delay":0,"ttmEps":-1.676,"open":29.12,"prevYearClose":16,"prevWeekClose":27.52,"prevMonthClose":26.1,"prevQuarterClose":22.26,"fiveDayClose":27.31,"twentyDayClose":27.23,"sixtyDayClose":19.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"SGP","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2026-05-14","symbol":"SGP","fiscalQuarterEnding":"2026/03","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.69},{"market":"US","date":"2026-03-26","symbol":"SGP","fiscalQuarterEnding":"2025/12","expectedEps":-6.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-5.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SGP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SGP","date":"2026-09-16","current":-17.064439,"percent":0.327586,"low":-21.652266,"twenty":-19.480412,"median":-16.248702,"eighty":-15.25235,"high":-14.017506,"avg":-16.956295,"sd":2.050612,"marketCap":968653471},"quantilePoints":[{"date":"2026-04-02","current":-20.423828,"twenty":-20.915203,"median":-19.976743,"eighty":-19.275615,"marketCap":814277598},{"date":"2026-04-10","current":-17.791054,"twenty":-19.887327,"median":-18.894548,"eighty":-18.2941,"marketCap":709311539},{"date":"2026-04-17","current":-20.985395,"twenty":-20.628232,"median":-19.259819,"eighty":-18.2941,"marketCap":836666721},{"date":"2026-04-24","current":-19.811622,"twenty":-20.628232,"median":-20.01284,"eighty":-18.750195,"marketCap":789869541},{"date":"2026-05-01","current":-19.233119,"twenty":-20.557806,"median":-19.76551,"eighty":-18.750195,"marketCap":766805217},{"date":"2026-05-08","current":-21.287223,"twenty":-20.628232,"median":-20.01284,"eighty":-18.869002,"marketCap":848700282},{"date":"2026-05-15","current":-20.348204,"twenty":-20.557806,"median":-19.991879,"eighty":-18.951807,"marketCap":811262538},{"date":"2026-05-22","current":-16.428664,"twenty":-20.542715,"median":-19.82839,"eighty":-18.248826,"marketCap":737055581},{"date":"2026-05-29","current":-16.634049,"twenty":-20.51924,"median":-19.719397,"eighty":-17.334564,"marketCap":663182890},{"date":"2026-06-05","current":-16.323837,"twenty":-20.485703,"median":-19.406541,"eighty":-16.365768,"marketCap":650815064},{"date":"2026-06-12","current":-15.166832,"twenty":-20.465581,"median":-18.98998,"eighty":-15.765344,"marketCap":604686416},{"date":"2026-06-18","current":-15.259057,"twenty":-20.45723,"median":-18.830682,"eighty":-15.591067,"marketCap":608363337},{"date":"2026-06-26","current":-14.017506,"twenty":-20.408703,"median":-18.172531,"eighty":-15.533886,"marketCap":628881407},{"date":"2026-07-02","current":-14.509349,"twenty":-20.348204,"median":-17.531147,"eighty":-15.527136,"marketCap":650947421},{"date":"2026-07-10","current":-14.956478,"twenty":-20.239211,"median":-16.634049,"eighty":-15.359666,"marketCap":671007434},{"date":"2026-07-17","current":-15.470677,"twenty":-20.105065,"median":-16.579363,"eighty":-15.259057,"marketCap":694076449},{"date":"2026-07-24","current":-15.560103,"twenty":-20.01284,"median":-16.428664,"eighty":-15.247112,"marketCap":698088452},{"date":"2026-07-31","current":-16.9313,"twenty":-19.979303,"median":-16.327675,"eighty":-15.249961,"marketCap":759605825},{"date":"2026-08-07","current":-14.762377,"twenty":-19.930676,"median":-16.460092,"eighty":-15.249961,"marketCap":827475536},{"date":"2026-08-14","current":-15.019457,"twenty":-19.846835,"median":-16.323837,"eighty":-15.098224,"marketCap":841885631},{"date":"2026-08-21","current":-15.651981,"twenty":-19.814976,"median":-16.231773,"eighty":-15.105016,"marketCap":877340489},{"date":"2026-08-28","current":-16.069685,"twenty":-19.737842,"median":-16.133919,"eighty":-15.15457,"marketCap":900754074},{"date":"2026-09-04","current":-17.29893,"twenty":-19.645616,"median":-16.12274,"eighty":-15.231056,"marketCap":969656911},{"date":"2026-09-11","current":-16.296439,"twenty":-19.568664,"median":-16.181307,"eighty":-15.249249,"marketCap":913464306},{"date":"2026-09-16","current":-17.281028,"twenty":-19.480412,"median":-16.248702,"eighty":-15.25235,"marketCap":968653471}],"updateTime":1789641070330},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657682776","title":"SpyGlass Pharma Q2 FY26 Net Loss Widens to $19.9 Million; R&D Expenses Rise to $10.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682776","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682776?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:37","pubTimestamp":1786048661,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma Q2 FY26 net loss widens to $19.9 million; R&D expenses rise to $10.9 millionSpyGlass Pharma posted a Q2 net loss of USD 19.9 million, or USD 0.59 per share, versus a loss of USD 8.7 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbnJTCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657812657","title":"Spyglass Pharma Q2 EPS USD -0.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2657812657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657812657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNGC6P8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657534","title":"Spyglass Pharma Q2 Pretax Profit USD -19.864 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657534?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNGC6P8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650991199","title":"Stockland Reports Lapse of 42,313 Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2650991199","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650991199?lang=en_us&edition=fundamental","pubTime":"2026-07-09 06:57","pubTimestamp":1783551449,"startTime":"0","endTime":"0","summary":"An update from Stockland ( ($AU:SGP) ) is now available. Stockland has reported the lapse of 42,313 performance rights, designated as SGPAA securit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-42313-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stockland-reports-lapse-of-42313-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504313","title":"Solana price clears $80 resistance as technicals point to $90 next","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504313","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504313?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:09","pubTimestamp":1782990541,"startTime":"0","endTime":"0","summary":"Solana price has erased much of June’s decline by reclaiming the $80 level, with record transaction activity and a technical breakout driving fresh optimism.Solana price has reclaimed the $80 level after record network activity and governance upgrades boosted buying momentum.Technical indicators favor further gains, with the next major resistance and liquidation cluster sitting near $90.Analysts remain divided as bullish momentum strengthens, while some traders warn the rally still faces key resistance.According to crypto.news data, Solana  price traded around $81.3 at the time of writing, up nearly 10% over the past 24 hours after breaking above the psychological $80 barrier for the first time in weeks. The recovery followed a series of network milestones that revived investor sentiment, while the broader crypto market also benefited from improving risk appetite after June’s steep correction.The next technical hurdle sits near the 50% Fibonacci retracement around $79.3, which has alre","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/solana-price-clears-80-dollar-resistance-as-90-next/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/solana-price-clears-80-dollar-resistance-as-90-next/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK7087","SGP.AU","SOL.AU","SOL.USD.HKCC","BK7510","SOLX","SSK","SOLT","SGP","GSOL","BSOL","BK7105","SLON","BK7083","SOLZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645555075","title":"Should Stockland’s A$250m Town Centre JV Shape the Income Story for ASX:SGP Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645555075","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645555075?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:22","pubTimestamp":1782127345,"startTime":"0","endTime":"0","summary":"Earlier today, Stockland announced a partnership with a Morgan Stanley Real Estate Investing vehicle to co-develop three new town centres worth about A$250 million, while reiterating its FY26 funds-from-operations and distribution guidance supported by strong recent sales across key residential segments.\nA key takeaway is how the sharp increases in masterplanned-community and land-lease net sales appear to underpin confidence in Stockland’s income outlook despite a challenging property...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/should-stocklands-a250m-town-centre-jv-shape-the-income-stor","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/should-stocklands-a250m-town-centre-jv-shape-the-income-stor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2271345857.HKD","LU0158827781.USD","LU0106261372.USD","LU0006306889.USD","LU0234570918.USD","LU1732800096.USD","LU2487616109.SGD","LU0528227936.USD","LU1988902786.USD","LU1720051108.HKD","LU0971096721.USD","LU2111349929.HKD","LU2089283258.USD","BK7510","LU0053666078.USD","BK4007","BK4534","IE00BKVL7J92.USD","BK4585","LU1791710582.SGD","BK4516","SGP","LU0795875086.SGD","LU1162221912.USD","LU0795875169.SGD","LU2357305700.SGD","LU1791710400.SGD","LU0314104364.USD","LU1244550494.USD","BK4581","LU1548497426.USD","LU0320765646.SGD","LU1720051017.SGD","LU0390134368.USD","LU2028103732.USD","LU2264538146.SGD","LU0098860793.USD","LU1244550221.USD","LU1064131342.USD","LU0267386448.USD","LU1244550577.SGD","LU0106831901.USD","LU1989772923.USD","SGP.AU","LU0912757837.SGD","LU1074936037.SGD","LU1732799900.SGD","ISBC","LU0557290698.USD","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203898","title":"SpyGlass Pharma appoints Shannon Treviño as general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203898","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203898?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:02","pubTimestamp":1781524972,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma appointed Shannon Trevio as general counsel as it advances the BIM-IOL System through Phase 3 trials.Trevio most recently served as general counsel and corporate secretary at Inari Medical, helping guide its USD 4.9 billion acquisition by Stryker.She previously worked at Sugg Law Group advising early-stage companies, taught transactional law at Loyola Marymount University, and practiced at Latham & Watkins.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL2KVzfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","LU0823417737.USD","LU2506952097.USD","LU0289739699.SGD","LU0950375773.USD","IE00B3QW5Z07.USD","LU2468319806.SGD","LU0823417653.USD","LU0690374615.EUR","LU2362541513.USD","BK4112","IE00B64PRP62.GBP","SYK","LU0882574055.USD","LU2404859741.USD","SG9999014005.SGD","BK4082","LU2095319765.USD","LU2362540622.SGD","LU0432979614.USD","LU1983299246.USD","LU2210150020.SGD","BK4007","IE00BN0W2V16.EUR","LU0058720904.USD","LU0690374961.EUR","LU1791710582.SGD","LU2362541273.HKD","IE00BKPKM429.USD","LU0114720955.EUR","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","SGP","GB00B4QBRK32.GBP","BK4566","LU2089984988.USD","LU1791710400.SGD","BK4504","IE00BN0W2T93.GBP","SG9999014021.USD","LU0528227936.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","LU2404859667.USD","LU2324357040.USD","LU2506952170.USD","GB00B4LPDJ14.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643080982","title":"Spyglass Pharma Appoints Shannon TreviÑO as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2643080982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643080982?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUABSWVC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643249505","title":"Is Stockland (ASX:SGP) Quietly Recasting Its Risk Profile With Morgan Stanley’s Capital-Light Partnership?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643249505","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643249505?lang=en_us&edition=fundamental","pubTime":"2026-06-14 16:17","pubTimestamp":1781425025,"startTime":"0","endTime":"0","summary":"In recent days, Stockland reported strong residential home-lot sales, record activity in its land-lease communities, and a new capital partnership with Morgan Stanley Real Estate Investing for neighbourhood shopping centres, supporting its capital-light growth approach.\nThese developments highlight how Stockland is using external capital and resilient housing demand to balance cyclical residential exposure with more stable, recurring property income.\nWe’ll now examine how this new Morgan...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551731-choice2-main-header/1585186650529"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/is-stockland-asxsgp-quietly-recasting-its-risk-profile-with","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/real-estate/asx-sgp/stockland-shares/news/is-stockland-asxsgp-quietly-recasting-its-risk-profile-with","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1720051108.HKD","LU0106261372.USD","LU0971096721.USD","LU1244550494.USD","LU1720051017.SGD","BK4588","BK4007","LU0314104364.USD","LU0098860793.USD","LU0882574139.USD","BK4534","LU1989772923.USD","LU0106831901.USD","LU2023251221.USD","LU1988902786.USD","LU0528227936.USD","AIPO","LU1074936037.SGD","LU2089283258.USD","BK4581","LU2264538146.SGD","LU0210528500.USD","IE00BZ1G4Q59.USD","LU0006306889.USD","LU0267386448.USD","LU0234570918.USD","LU1162221912.USD","LU0225283273.USD","BK7510","LU1732799900.SGD","LU0053666078.USD","LU0390134368.USD","LU2111349929.HKD","LU2271345857.HKD","LU1989772840.SGD","LU1244550577.SGD","LU2089284900.SGD","BK4504","BK4585","LU2487616109.SGD","SGP.AU","LU2133065610.SGD","BK7087","SGP","LU0557290698.USD","LU1668664300.SGD","LU1244550221.USD","LU0320765646.SGD","LU1363072403.SGD","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910404","title":"Spyglass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910404?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA1NHWQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948859","title":"SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948859","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948859?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., June  02, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305080/0/en/SpyGlass-Pharma-Appoints-Mike-Pinder-as-Vice-President-Marketing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639383622","title":"Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Fiserv (FISV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639383622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639383622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:40","pubTimestamp":1780054816,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on SpyGlass Pharma (SGP) and Fiserv (FISV). SpyGlass Pharma (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spyglass-pharma-sgp-and-fiserv-fisv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","LU0980610538.SGD","LU1923622291.USD","LU0130103400.USD","NA","LU1046421795.USD","BK4588","LU0354030438.USD","BK4141","LU0354030511.USD","SGP","LU0648001328.SGD","LU2125909759.SGD","LU1201861249.SGD","FISV","LU1861220207.SGD","LU0208291251.USD","LU1861217088.USD","LU2125909916.SGD","LU0070302665.USD","LU0130102774.USD","LU1201861165.SGD","BK4007","BK4227","BK4585","LU0648000940.SGD","LU1823568750.SGD","BK4106"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333415","title":"SpyGlass Pharma management joins Stifel virtual ophthalmology forum fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333415?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364824,"startTime":"0","endTime":"0","summary":"Spyglass Pharma executive management will take part in investor conference sessions on May 26, June 4, June 10.Events include fireside chats at the Stifel 2026 Virtual Ophthalmology Forum on May 26 and the Jefferies Global Healthcare Conference on June 4.A corporate presentation is scheduled for the Goldman Sachs 47th Annual Global Healthcare Conference on June 10.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7FFqJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU2237443978.SGD","BK4112","LU2237443549.SGD","IE00BFXG1179.USD","LU1868836914.USD","IE0004091025.USD","BK4585","BK4504","IE0034235188.USD","BK4127","SG9999014039.USD","LU2750360997.AUD","NDAQ","BK4552","GSX","LU0061475181.USD","LU0314104364.USD","LU2471134796.USD","LU1868836757.USD","LU0251142724.SGD","LU0096364046.USD","BK4550","LU0251131958.USD","IE00BN0W2T93.GBP","LU0106831901.USD","IE0004086264.USD","LU2471134523.USD","LU2237443622.USD","LU2210150020.SGD","LU2237443465.HKD","SG9999014005.SGD","IE00BGHQF748.EUR","LU1804176565.USD","LU1668664300.SGD","SG9999014021.USD","SF","SGP","LU1791807156.HKD","LU1868837300.USD","LU1894683264.USD","LU2210149790.SGD","LU2750360641.GBP","LU2237438978.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2471134952.CNY","LU0942090050.USD","IE00B19Z3B42.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333066","title":"SpyGlass Pharma to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333066?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"ALISO VIEJO, Calif., May  21, 2026  (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299275/0/en/SpyGlass-Pharma-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636586310","title":"Jefferies Sticks to Its Buy Rating for SpyGlass Pharma (SGP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586310?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:55","pubTimestamp":1779209724,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding maintained a Buy rating on SpyGlass Pharma today and set a price target of $62.00. Ding covers the Healthcare sector,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-spyglass-pharma-sgp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636733940","title":"Spyglass Pharma Inc - Bim-Iol System Phase 3 Trial Enrollment Expected to Complete in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636733940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636733940?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:04","pubTimestamp":1779105868,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073386","title":"SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073386","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073386?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":"Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercializationALISO VIEJO, Calif., May  18, 2026  (GLOBE NEWSWIRE) -- SpyGla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296580/0/en/SpyGlass-Pharma-Announces-New-Add-on-Category-III-CPT-Code-for-Its-Innovative-BIM-IOL-System.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","III","BK4215","AMA","BK4007","BK4134","CPT","SGP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608713","title":"Spyglass Pharma publishes deck on long-acting intraocular drug delivery for glaucoma patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608713","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608713?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:10","pubTimestamp":1778850620,"startTime":"0","endTime":"0","summary":"Spyglass Pharma outlined Phase 3 pivotal trials underway for BIM-IOL System, an intraocular lens drug-delivery product designed to provide about 3 years of bimatoprost therapy for open-angle glaucoma or ocular hypertension at time of routine cataract surgery.First-in-human feasibility data showed 95% of patients off topical IOP-lowering therapy at 36 months, with 37% mean IOP reduction across doses.Phase 1/2 results with intended commercial dose of 78 mcg showed 98% of patients off topical IOP-lowering therapy at 12 months, with 34% mean IOP reduction.Company pegged BIM-IOL System addressable U.S. market at about USD 13 billion, citing an estimated 1,000,000 U.S. glaucoma or ocular hypertension patients projected to undergo cataract surgery in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2y9lT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635299137","title":"SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635299137","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635299137?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:04","pubTimestamp":1778792661,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of $(3.96) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52583721/spyglass-pharma-q1-eps-0-69-misses-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635838726","title":"Spyglass Pharma Q1 FY26 net loss widens 57% to $13.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635838726","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635838726?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:33","pubTimestamp":1778790805,"startTime":"0","endTime":"0","summary":"Spyglass Pharma posted a net loss of USD 13.82 million, widening 57% year over year, as operating loss widened to USD 15.41 million.Research and development expense rose 41% to USD 8.54 million, while general and administrative costs more than doubled to USD 6.87 million.Interest income climbed to USD 1.59 million from USD 126,000 a year earlier.Cash and cash equivalents and short-term investments totaled USD 251 million as of March 31, 2026, following USD 157.76 million of net cash provided by financing activities tied mainly to IPO proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retriev","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL4Pvlvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}